We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Prostate Cancer Drugs Undergoing FDA Safety Review for CV Risks
Prostate Cancer Drugs Undergoing FDA Safety Review for CV Risks
May 3, 2010
The FDA is conducting a safety review of a class of commonly used prostate cancer drugs in light of a safety signal showing they may pose a small increased
risk for diabetes and cardiovascular (CV) disease in men treated with the medications.